



130th MAINE LEGISLATURE

LD 673

LR 1953(04)

An Act To Create the Insulin Safety Net Program

Fiscal Note for Bill as Engrossed with:

C "A" (S-278)

Committee: Health Coverage, Insurance and Financial Services

Fiscal Note

Current biennium revenue increase - Other Special Revenue Funds

	FY 2021-22	FY 2022-23	Projections FY 2023-24	Projections FY 2024-25
Appropriations/Allocations				
Other Special Revenue Funds	\$85,265	\$110,138	\$116,401	\$123,041
Transfers				
Other Special Revenue Funds	\$0	\$0	\$0	\$0

Fiscal Detail and Notes

This bill includes Other Special Revenue Funds allocations to the Department of Professional and Financial Regulation totaling \$85,265 in fiscal year 2021-22 and \$110,138 in fiscal year 2022-23 to establish the Insulin Safety Net Program within the Office of Professional and Occupational Licensing, Maine Board of Pharmacy.

Of this amount, Other Special Revenue Funds allocations of \$81,906 in fiscal year 2021-22 and \$105,951 in fiscal year 2022-23 are provided to the Licensing and Enforcement program to establish one Comprehensive Health Planner position and related All Other costs to manage the program. Additional allocations of \$630 and \$840 in fiscal years 2021-22 and 2022-23, respectively, are included for the per diem costs for one board member to review a manufacturer's determination of eligibility for the manufacturer's patient assistance program if requested by the applicant. Finally, Other Special Revenue Funds allocations of \$2,729 in fiscal year 2021-22 and \$3,347 in fiscal year 2022-23 are included for the Administrative Services Division for technology-related costs associated with establishing the Comprehensive Health Planner position. The Office of Professional and Occupational Licensing will transfer funds from its Licensing and Enforcement program (which includes funds for the Maine Board of Pharmacy) to the Administrative Services Division to fund the allocations.

This legislation will result in an increase in dedicated revenue to the Maine Board of Pharmacy from the required \$75,000 registration fee that certain insulin manufacturers must pay each year until it is repealed on January 1, 2027.